

Special Issue

Splicing: The New Frontier in Therapeutics

Message from the Guest Editor

For a long time only genetic disease with splicing mutations were on the radar of the splicing therapeutics development; however, it is now clear that principles of splicing therapeutics may be applied to virtually any disease.

Distinct splicing therapeutics ideas have been appearing in the field that mainly aggregate into two classes:

a. splicing inhibitors – usually small molecules that target core components of the spliceosome, whose utility is explored mainly in cancers with mutations in these components; b. alternative splicing modulation of specific splicing events – this is a form of targeted therapy that intends to switch a splice isoform (or ratio of splice isoforms) characteristic of disease, to a normal expression pattern therefore functionally rescuing the phenotype

I believe that splicing therapeutics is an emerging field with potential for great expansion in the future and therefore invite in this special issue submission of reviews or research articles in any area of disease and therapeutics where a splicing component or mechanism is involved.

Guest Editor

Dr. Sebastian Oltean

Department of Clinical & Biomedical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter EX1 2LU, UK

Deadline for manuscript submissions

closed (20 May 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/47029

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))